Alexandre Abizaid, Ricardo Costa, Sasko Kedev, Elvin Kedhi, Suneel Talwar, Andrejs Erglis, Ota Hlinomaz, Monica Masotti, Farzin Fath-Ordoubadi, Krzysztof Milewski, Pedro Lemos, Roberto Botelho, Alexander Ijsselmuiden, Jacques Koolen, Petr Kala, Luc Janssens, Udita Chandra
BACKGROUND: Drug-eluting stents (DESs) based on biodegradable polymers (BPs) have been introduced to reduce the risk for late and very late stent thrombosis (ST), which were frequently observed with earlier generations of DES designs based on durable polymers (DPs); however, randomized controlled trials on these DES designs are scarce. The meriT-V trial is a randomized, active-controlled, non-inferiority trial with a prospective, multicenter design that evaluated the 2-year efficacy of a novel third-generation, ultra-thin strut, BP-based BioMime sirolimus-eluting stent (SES) versus the DP-based XIENCE everolimus-eluting stent (EES) for the treatment of de novo lesions...
August 2023: Cardiology Research